Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Microchip Technology heads into its November 5 earnings print with short sellers quietly adding exposure and the stock still trading well below where most analysts think it belongs.
Short interest has been building steadily. It reached 6.5% of the free float by October 6, up 5% on the week and 7.4% over the past month. That is not an extreme level by semiconductor standards, but the direction is consistent and the pace has picked up. The borrow market remains easy: availability is exceptionally loose at 2,516%, meaning shares to borrow are plentiful relative to current short interest. Cost to borrow is just 0.45%, up modestly on both a weekly and monthly basis but still well within the "easy to borrow" range. The ORTEX short score has drifted up from 40.5 on September 24 to 43.4 on October 6, a measured rise rather than a spike, suggesting positioning is becoming more cautious without yet signalling any kind of conviction short thesis. Options confirm the same read: the put/call ratio of 0.48 sits just barely above its 20-day average of 0.47, a z-score of 0.20, essentially neutral.
The Street is broadly constructive but not uniformly so, and the gap between price and target is the clearest tension. At $81.26, the stock trades more than 30% below the mean analyst price target of $107.84. The recent round of analyst updates, most of which landed around the August earnings date, showed a split: UBS and Citigroup both maintained Buy ratings while cutting their targets (to $120 and $95 respectively), and Cantor Fitzgerald reiterated Overweight with a $125 target. Truist and TD Cowen held at Hold with targets in the $88 to $90 range, closer to where the stock is trading now. BMO initiated coverage at Outperform with a $95 target in late August. Taken together, the bull camp points to data center momentum, 97.8% year-on-year growth in June-quarter data center sales, 12 PCIe Gen6 design wins, and a $1 billion data center revenue target for calendar 2026. The bear camp flags that MCUs still account for roughly 53% of revenue, leaving the company exposed to any reversal in cyclical demand, and raises questions about inventory write-down disclosure and whether gross margins have an artificial tailwind. The PE multiple of 18.6x and EV/EBITDA of 15.6x have both expanded over the past 30 days, consistent with the stock's 9.6% one-month gain, though both are compressing slightly over the past week as the recovery moderates.
The institutional picture adds nuance. BlackRock added a substantial 9.3 million shares in the period to September 30, lifting its stake to 11.7% of shares. State Street and Van Eck also added modestly. The most notable activist register entry is the Vanguard reorganisation: The Vanguard Group filed a 13G/A in March 2026 showing its stake had fallen to zero, while two separate Vanguard management entities subsequently filed 13Gs showing combined ownership of roughly 13% of shares. No 13D activist is on the register. As with all 13D/G disclosures, stakes are as last reported and holders below the 5% threshold may exit without a further filing. On the insider side, the 90-day net is modestly negative at around 4,900 shares sold on a net basis, worth roughly $377,000. The CFO's August 25 sale of 4,112 shares for $310,000 was made under a pre-arranged 10b5-1 plan, which limits its signalling value. The small September grants to senior vice presidents are routine compensation awards, not open-market activity.
Earnings history adds some texture to the setup. The most recent print on August 6 produced a one-day gain of 8.9%, but the five-day return faded to near flat at minus 0.1%, a pattern that suggests initial relief on results can dissipate quickly if the forward guidance disappoints or fails to extend the initial optimism. The prior event in August 2026 showed a one-day loss of 4% and a five-day loss of 8.4%, a reminder that moves in both directions have been material. With 29 days to the next report and Wikipedia attention running above its own 90-day average (a z-score of 1.7), retail interest in the name is ticking up.
The next 29 days will therefore test whether the stock's 9.6% one-month recovery can hold into the print, and whether data center growth momentum is broad enough to offset any softness in the MCU-heavy core, which is the question neither the bulls nor the bears have fully resolved.
See the live data behind this article on ORTEX.
Open MCHP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
